Bronchodilators on the Exercise Capacity of Bronchiectasis Patients

• Status: Suspended
• Trial end date: 2024-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The bronchodilators (BD) have been widely used in bronchiectasis (BCE) therapeutic and have been shown to be effective in improving exercise capacity in patients with chronic obstructive pulmonary disease and asthma. However their effect on the exercise capacity of patients with BCE is poorly known. Besides, their respiratory mechanics pattern is also not known neither their physical activity level (PAL). Therefore, the hypothesis of this study is that BD are effective in improving exercise capacity of BCE patients. We aim also to characterize their respiratory mechanics and to evaluate their PAL and its association to their quality of life.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Sao Paulo General Hospital
• Treatments: Bronchodilator Agents; Fenoterol; Ipratropium

Criteria

Inclusion Criteria:

• All sexes

• 18 to 60 years

• Bronchiectasis diagnosis, according to thorax CT(Pasteur et al., 2010)

• Clinically stable (last 30 days without exacerbation/hospitalization)

• Air trapping on plethismography (RV/TLC>125%)

• Smoking Load <10 pack-years

Exclusion Criteria:

• Do not accept to paticipate

• Smoking

• Continuous oxygen use

• Pulmonary Rehabilitation program in the last 6 months

• Previous lung ressection

• Uncontrolled Cardiovascular disease

• Other respiratory chronic diseases

• Neurological or musculoskeletal disorders that limit exercise

• Cognitive deficits that limit comprehension